Manipal Health Enter

The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to fix typo in headline

By Ujjaini Dutta

BENGALURU, Sept 4 (Reuters Breakingviews) - New Delhi will hurt itself if it puts foreign funding for its healthcare system under the knife. A day after U.S. private equity firm KKR KKR.N agreed to buy Medicover's MCOVb.ST India hospitals business for $1.4 billion, a parliamentary panel urged the government to "review and rationalise" overseas funding, shield smaller providers from "predatory corporate buyouts" and cap room rates at the equivalent of three-star hotels. Adopting those measures may be politically appealing but it will ultimately worsen India's chronic shortage of healthcare capacity.

The impulse to increase affordability is easy to understand. Woefully low public spending leaves the majority of Indians depending on private hospitals where annual medical inflation rate is running at up to 13%, per the committee report. Though the amount paid out of pocket to cover bills is reducing, it remains high at 44%, roughly three times that of the United Kingdom, Australia and Canada.

Yet price rises reflect a maturing industry, more than fraud and waste. Most external investment flows to big cities led by Bengaluru, Mumbai and New Delhi where affluent populations want cutting-edge treatment. Restricting capital inflows will slow the pace of technology advancement and growth: India still has just 16 hospital beds per 10,000 people, compared to China's 56 and Japan's 126.

Take Manipal Health Enterprises MNIA.NS . Singapore's Temasek first invested in the Bengaluru-based company in 2017, became its controlling shareholder in 2023 and retains a 44% stake after the $10 billion hospital chain's IPO last month. During that time, Manipal Health acquired five rivals, comprised of 31 hospitals but it plans to add another 1,943 beds to its current 13,037 through greenfield projects through 2030. Blackstone BX.N, CVC and others have made similar investments.

Capping room rates won't materially improve affordability either. These account for just 12% of a patient's total bill over a four night stay based on an average room tariff of 8,000 rupees ($84.25) and average revenue per bed of 68,767 rupees, according to Breakingviews calculations using data from Fortis Healthcare FOHE.NS and Visible Alpha. Hospitals would simply try to recover the difference by charging more for procedure costs or doctor fees as they did when the government capped stent prices in 2017. Worse, benchmarking rates to nearby three-star hotels as proposed would leave much to be desired in quality of accommodation, even for the non-fussy among India's well-heeled.

Standardising treatment costs and enforcing faster claim dispute resolution are better ways to reduce unnecessary medical inflation for those that can afford to pay. Blaming foreign investors for problems arising from India's miserly spending on public health, at less than 2% of GDP, would be a costly misdiagnosis.

Follow Ujjaini Dutta on LinkedIn and X.

CONTEXT NEWS

A parliamentary committee on August 7 recommended the government “strictly review and rationalize" foreign investment in healthcare facilities and protect affordable mid-sized hospitals from "predatory corporate buyouts”.

The “Affordability and Accessibility of Healthcare Facilities in Public and Private Sector” report said that "aggressive corporatization is fundamentally transforming healthcare from a public service sector into a purely capitalistic enterprise, artificially inflating the cost of medical procedures and triggering a cascading effect of price hikes across the entire healthcare ecosystem".

The report also recommends that the room charges for a hospital should be capped to average room tariffs in three-star hotels in the peripheral area or vicinity of the hospital.

(Editing by Una Galani; Production by Aditya Srivastav)

((For previous columns by the author, Reuters customers can click on DUTTA/[email protected]))

** HSBC initiates Manipal Health Enterprises MNIA.NS with "Buy" and PT of 1,000 rupees

** Brokerage expects hospital operator to focus on improving asset utilisation and operational profitability, after doubling bed capacity since FY23

** Brokerage sees clear scope for revenue and earnings growth, supported by better EBITDA margins after acquiring Sahyadri Hospitals, an improved hospital mix, plans to add about 2,500 beds in fiscal 2027-2030, and a strong balance sheet

** Estimates EBITDA CAGR at 19.3% over FY26-29e; estimates revenue CAGR at 17.9% over the same period

** Shares down 0.9% at 791.2 rupees

** Stock up 21.4% since trading debut on August 5

(Reporting by Mridula Kumar in Bengaluru)

(([email protected]))

** Shares of Manipal Health Enterprises MNIA.NS fall as much as 3.5% to 699 rupees

** Co's June quarter consolidated net profit fell 7.5% year-on-year due to costs related to the acquisition of Sahyadri Hospitals

** Q1 revenue rose 38.1% y/y, boosted by higher patient volumes, increasing share of high-value specialty procedures

** This marks hospital operator's first quarterly earnings since listing on Aug 5

** Stock up 9.12% from IPO price

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

Aug 20 (Reuters) - Manipal Health Enterprises Limited MNIA.NS:

• JUNE-QUARTER CONSOL NET PROFIT 2.32 BILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 30.91 BILLION RUPEES

Further company coverage: MNIA.NS

(([email protected];;))

Aug 18 (Reuters) - Manipal Health Enterprises Limited MNIA.NS:

• MANIPAL HEALTH ENTERPRISES LIMITED - TO ACQUIRE KINDER WOMEN’S HOSPITAL IN BENGALURU

• MANIPAL HEALTH ENTERPRISES LIMITED - ACQUISITION FOR A CASH CONSIDERATION OF 1.3 BILLION RUPEES

Source text: [ID:]

Further company coverage: MNIA.NS

(([email protected];))

Manipal Health Enterprises' promoters disclosed pledges, non-disposal undertakings and financing covenants covering 36.90 crore shares, equivalent to 27.70% of the company's fully diluted share capital and 100% of promoter holdings. The arrangements secured facilities and unlisted non-convertible debentures associated with group entities, with ₹15,905 crore of financing reported against shares valued at ₹7,873 crore, a security-cover ratio of 0.49. Deutsche Bank, Axis Trustee Services, Vistra ITCL and 360 One Prime appeared as agents, trustees or lenders in the arrangements. The stated uses included debt repayment, investments, general corporate purposes and tax payments, while the listed company was not a party to the agreements. Some of the encumbrances existed before Manipal Health Enterprises' listing on August 5, 2026, while others were created afterward.

Powered by Tijori

Axis Trustee Services, acting as onshore security agent, disclosed an encumbrance over 116,633,996 shares of Manipal Health Enterprises held by Manipal Global Health Services and Cypress Holdings, securing a term-loan facility from certain lenders. The encumbrance represented 8.86% of voting share capital and 8.75% on a fully diluted basis. The trustee said it held no beneficial interest in the shares. The disclosure followed the listing of Manipal Health Enterprises on August 5, 2026.

Powered by Tijori

Rewrites, adds analyst comment in paragraphs 6-7

Aug 5 (Reuters) - Manipal Health Enterprises MNIA.NS rose sharply in its market debut on Wednesday, valuing India's largest multispecialty hospital network at about $9.03 billion.

The shares rose as much as 10.7% to 653.10 rupees on the National Stock Exchange of India, compared with the issue price of 590 rupees. India's benchmark Nifty .NSEI was trading 0.06% higher.

The $960 million IPO was India's second-largest this year, behind SBI Funds Management's SBIA.NS listing in July.

Temasek-backed Manipal Health, which operates more than 13,000 beds across 49 hospitals, is betting on rapidly growing demand for specialised healthcare options, which analysts say will form the bedrock of growth in the Indian healthcare market. The sector is booming with increasing private and foreign investments from the likes of Blackstone BX.N, Novo Nordisk NOVOb.CO and KKR KKR.N.

The strong listing reflects healthy investor demand, but its premium valuation leaves limited upside in the near term, said Shivani Nyati, head of wealth at Swastika Investmart.

"Investors who received the allotment can continue to hold the stock, while fresh investors should wait for better entry levels or signs of further debt reduction before buying," Nyati said.

Apollo Hospitals APLH.NS, Manipal Health's closest listed rival with a market capitalisation of around 1.3 trillion rupees, has nearly 10,000 beds and aims to expand its capacity to 13,000 beds by fiscal 2030.

Max Healthcare MAXE.NS and Fortis Healthcare FOHE.NS have a market cap of 1.04 trillion rupees and 704.22 billion rupees, respectively.

Manipal Health plans to spend 40 billion rupees to increase its bed capacity by over 18% in the next few years, adding 2,400 beds within three to four years.

The company is valued at 84.65 times its fiscal 2026 earnings at the upper end of the IPO price band of 560 rupees to 590 rupees, brokerage Angel One said in a note. Apollo, Fortis and Max Healthcare are valued between 66.15x and 74.55x.

($1 = 94.9725 Indian rupees)

(Reporting by Urvi Dugar, Surbhi Misra and Vivek Kumar M in Bengaluru; Editing by Janane Venkatraman, Sonia Cheema and Mrigank Dhaniwala)

(([email protected]; +91 9558725583;))